SynOx Therapeutics is focused on developing targeted therapies for diffuse tenosynovial giant cell tumors using advanced biopharmaceutical techniques. The company aims to provide effective treatment options for patients suffering from this rare and aggressive tumor type, addressing a significant unmet medical need in oncology.
Funding
$135.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GHFounders
Product
Problem
Tenosynovial giant cell tumors (TGCT) are rare, aggressive tumors with limited effective treatment options, resulting in a significant unmet medical need in oncology. These tumors, driven by macrophage activity, can cause pain, swelling, and reduced mobility, severely impacting patients' quality of life.
Solution
SynOx Therapeutics is developing emactuzumab, a monoclonal antibody targeting CSF-1R, as a targeted therapy for TGCT and other macrophage-driven pathologies. Emactuzumab aims to inhibit the colony-stimulating factor 1 receptor (CSF-1R), a key regulator of macrophage activity, to reduce tumor size and alleviate associated symptoms. By selectively targeting CSF-1R, the therapy seeks to provide a more effective and tolerable treatment option compared to existing approaches. This approach has the potential to address the underlying cause of TGCT by modulating the tumor microenvironment and controlling macrophage-mediated inflammation.
Target Audience
The primary target audience includes patients diagnosed with tenosynovial giant cell tumors (TGCT) and potentially individuals with other macrophage-mediated diseases.
Features
- Emactuzumab: A monoclonal antibody specifically targeting CSF-1R
- Designed to inhibit macrophage activity in TGCT tumors
- Potential application in other macrophage-driven diseases